Lilly reports that self-pay is now most new Zepbound prescriptions

Eli Lilly told investors on August 5 that the self-pay segment accounted for 45% of total Zepbound prescriptions and 55% of new prescriptions during the second quarter of 2026 ^[2]. That makes cash-pay the majority route for people starting tirzepatide for obesity in the U.S., rather than the exception.

The disclosure came alongside Lilly's Q2 2026 results, which showed company-wide revenue of $23.0 billion, up 48% from a year earlier, driven mainly by Mounjaro and Zepbound volume ^[1]. U.S. Zepbound revenue rose 44% to $4.9 billion, which Lilly attributed to "strong demand, partially offset by lower realized prices, including previously announced reductions in cash-pay prices" ^[1]. (The company's product table shows a 46% increase for Zepbound overall, which includes Canada and Japan, while the 44% figure refers to the U.S. ^[1].)

Prices are falling as cash volume rises

The pricing picture in Lilly's numbers is unusual: volume up sharply, price down. U.S. revenue grew 33% to $14.4 billion on a 37% increase in volume, partially offset by a 3% decrease in realized prices ^[1]. Lilly said that decline was driven primarily by Zepbound and Mounjaro, and that adjustments to rebate and discount estimates softened the drop. Excluding those adjustments, CFO Lucas Montarce said U.S. price "declined by 9%" ^[1][2].

In other words, the average amount Lilly actually collects per prescription is shrinking, and a growing share of that revenue is coming directly from patients' wallets instead of from insurers after rebates.

At the same time, insurance coverage is expanding in one specific place. Lilly said a Medicare GLP-1 Bridge program launched July 1 gives roughly 20 million Americans coverage for obesity treatment with a $50 monthly out-of-pocket cost, and that the program increased the number of people in the U.S. with coverage for Lilly's obesity medicines by about 35% ^[2]. That program started after the quarter that the 55% figure describes, so its effect on the self-pay mix is not yet reflected in these numbers.

What the sources do not say is equally important. Lilly did not break out, in these materials, how much a month of Zepbound costs at each cash-pay dose or channel, how many self-pay patients are uninsured versus denied coverage by a plan, or how many switch back to insurance later. Those details are not in the sources reviewed here.

Why it matters for patients

For years the first question for anyone considering Zepbound was whether a health plan would pay. Lilly's own prescription mix suggests that for most people starting the drug now, that question has been answered "no" — or has been skipped entirely in favor of paying cash ^[2]. Practically, that shifts the comparison shopping from formulary tiers and prior-authorization paperwork to list cash prices, vial versus pen formats, and refill timing.

The falling realized price is a double-edged data point. Lower cash prices are why Lilly's per-prescription revenue is down ^[1], which is good news for out-of-pocket budgets. But price cuts made by a manufacturer can be changed by that manufacturer, and nothing in these results commits Lilly to holding current cash prices.

Medicare-eligible readers are in a different position than commercially insured ones as of July 1, given the Bridge program's $50 monthly out-of-pocket figure ^[2]. The details of eligibility and which products qualify are not spelled out in the sources here.

What happens next

• Later in 2026: Lilly completed its U.S. submission of Foundayo (orforglipron), an oral GLP-1, for type 2 diabetes and expects regulatory action by year-end ^[1][2]. Foundayo posted $98 million in first-quarter-of-launch revenue, with the prescriber base rising to 36,000 from 8,000 ^[2]. A cheaper-to-make oral option could change cash pricing dynamics, though Lilly has not published U.S. obesity cash prices for it in these materials.
• First quarter of 2027: Lilly plans to submit a Biologics License Application to the FDA for retatrutide, its triple-agonist obesity candidate, saying the clinical package is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain ^[1].

Lilly's next quarterly update will show whether the Medicare program pulls the self-pay share back below half.